Sartorius Stedim Biotech Invests Heavily in Marseille

The Aubagne-based Sartorius Stedim Biotech Group has just announced a massive new investment of $113 million (€100 million). This world leader in single-use consumables for large pharmaceutical laboratories had deployed a $26 million (€23 million) R&D and cleanroom construction program in 2018 to increase its production capacity by 30%. This time, the company is committing a $113 million (€100 million) plan to expand its Provencal manufacturing facility by another 4,000 square meters. This expansion, scheduled for 2023, will almost double the size of the plant.

It will be accompanied in the same year by the construction of a new 10,000 square meter logistics warehouse and the creation the following year of an additional 2,000 square meter research laboratory. Finally, the investment will allow the digitization and automation of the process, the reinforcement of the workforce, and the modernization of the group’s two other units in France, in Lourdes (80 people) and in Cergy (35 people).

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech. The Born2Invest mobile app is available for free for both Android and iOS devices.

Sartorius received $20.3 million (€18 million) in aid

For the first phase of this plan, Sartorius Stedim Biotech received $5 million in funding from local authorities. This time, the government has put its hand in its pocket by releasing a total of $20.3 million (€18 million).

“Sartorius is a concrete example of what we want for our healthcare industry. Our goal is to be able to produce strategic medical products and devices on our soil in the event of a crisis,” explained the Minister of Industry, Agnès Pannier-Runacher, when announcing the plan. “It’s about increasing our capacity and competitiveness to meet the just-in-time delivery requirements of the biopharmaceutical industry,” added Luc Burgard, CEO of the unit, which was formed in 2007 from the merger of the biotechnology division of Germany’s Sartorius AG with the French sterile bag supplier Stedim, which is now listed on the Paris stock exchange.

Presence in 20 countries

The company works for all vaccine manufacturers. It supplies them with bioreactors, fermenters, cell culture media, live-cell imaging, and analysis systems, pipetting instruments, protein analysis, and water purification and weighing technologies, among other things. Since the acquisition of the Slovenian company BIA Separations last year for 360 million euros, the company also has “a unique technology for the purification of large biomolecules, such as viruses, plasmids, and messenger RNA.

The Group is present in more than 20 countries in Europe, North America, and Asia, with sales of $2.15 billion (€1.91 billion) and 7,500 employees in 2020. This new project will create 400 permanent jobs in France by 2025.

__

(Featured image by nattanan23 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LesEchos, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.